The Journal of Thoracic and Cardiovascular Surgery
Volume 137, Issue 1 , Pages 13-19, January 2009

POINT: Clinical stage IA non–small cell lung cancer determined by computed tomography and positron emission tomography is frequently not pathologic IA non–small cell lung cancer: The problem of understaging

Division of Thoracic Surgery, New York Presbyterian Hospital-Weill Medical College of Cornell University, New York, NY

Received 2 May 2008; received in revised form 18 August 2008; accepted 19 September 2008.

Objective

There is an increase in interest in limited resection for clinical stage IA non–small cell lung cancer. The purpose of this study was to evaluate the accuracy of the diagnosis of clinical stage IA non–small cell lung cancer when determined by both computed tomography and positron emission tomography scans and to determine factors associated with understaging.

Methods

A retrospective review of a prospectively maintained database of patients with non–small cell lung cancer was performed. Patients with clinical stage IA cancer determined by preoperative computed tomography and positron emission tomography scan were reviewed. The influence of the following factors was analyzed with regard to accuracy of clinical staging: tumor size, location, histology, and positron emission tomography positivity.

Results

Of the 266 patients identified, cancer was correctly staged in 65%. Final pathologic stages also included IB (15%), IIA (2.6%), IIB (4.1%), IIIA (4.9%), IIIB (7.5%), and IV (.08%). Positive lymph nodes were found in 11.7% of patients. Pathologic T classification changed in 28.2% of patients. Cancer in patients with clinical tumor size greater than 2 cm (n = 68) was significantly more likely to be understaged than in patients with tumors 2 cm or less (49% vs 29%, P = .003). Cancer in patients with a positron emission tomography-positive (positron emission tomography +VE) primary evaluation (n = 218) was also more likely to be understaged (39% vs 15%, P = .001). Of patients with positron emission tomography +VE tumors greater than 2 cm, cancer was clinically understaged in 55%, compared with 32% for positron emission tomography +VE tumors 2 cm or less, and only 17% for positron emission tomography negative (−VE) tumors less than 2 cm.

Conclusion

Clinical stage IA lung cancer is frequently understaged in patients. Size greater than 2 cm and positron emission tomography positivity are risk factors for understaging. Limited resection should be undertaken with caution in such patients.

Abbreviations and Acronyms: CALGB, Cancer and Leukemia Group B, CT, computed tomography, NSCLC, non–small cell lung cancer, PET, positron emission tomography, SUV, standardized uptake value, VPI, visceral pleural invasion

CTSNet classification: 10

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

 This paper was presented at the 2008 American Association for Thoracic Surgery (AATS) meeting in the point-counterpoint session.

PII: S0022-5223(08)01637-1

doi:10.1016/j.jtcvs.2008.09.045

The Journal of Thoracic and Cardiovascular Surgery
Volume 137, Issue 1 , Pages 13-19, January 2009